LOGIN  |  REGISTER
Cue Biopharma

Artivion (NYSE: AORT) Stock Quote

Last Trade: US$19.18 0.16 0.84
Volume: 127,111
5-Day Change: -5.38%
YTD Change: 7.27%
Market Cap: US$790.790M

Latest News From Artivion

Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis Achieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency... Read More
ATLANTA , Feb. 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and... Read More
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion 72% Reduction in All-Cause Mortality and 52% Reduction in Primary Major MAEs when Compared to Current Standard of Care Hemi-arch Procedure ATLANTA , Jan. 29, 2024 /PRNewswire/ -- Artivion, Inc.... Read More
Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of a comprehensive, non- dilutive definitive credit agreement with Ares Management Credit funds for $350 million... Read More
Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA , Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023 . In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee ,... Read More
ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PERSEVERE clinical trial. The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS... Read More
ATLANTA , Nov. 8, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at the Lotte New York Palace. The Company's presentation is scheduled to begin at... Read More
Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 12% on a non-GAAP constant currency basis Net loss was ($9.8) million or ($0.24) per share; non-GAAP net income was $749,000 or $0.02 per share Non-GAAP adjusted EBITDA increased 34% to $13.9 million in the third quarter of 2023... Read More
ATLANTA , Oct. 19, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023 financial results will be released on Thursday, November 2, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session... Read More
Late-Breaking Science Presented at the 37 th European Association for Cardio-Thoracic Surgery Annual Meeting ATLANTA , Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X Aortic Heart Valve Low INR post-market study presented in a Late-Breaking Science session at the 37 th European Association for... Read More
Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS ATLANTA , Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the AMDS PERSEVERE clinical trial in a Late-Breaking Science presentation at the 37 th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna,... Read More
ATLANTA , Sept. 26, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 31 st Annual Leveraged Finance Conference on Tuesday, October 3, 2023. The Company's presentation is scheduled to begin at 10:40 a.m. MST . A live webcast of the presentation will be accessible through Artivion's... Read More
ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21 , 2023. The Company's presentation is scheduled to begin at 11:00 a.m. ET . A live webcast of the presentation will be accessible through... Read More
Second Quarter and Recent Business Highlights: Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a GAAP and non-GAAP constant currency basis Net loss was ($3.4) million or ($0.08) per share; non-GAAP net income was $2.3 million or $0.06 per share Achieved EBITDA of $9.2 million in the second quarter of 2023; non-GAAP adjusted EBITDA... Read More
ATLANTA , Aug. 1, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in three upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 43 rd Annual Growth Conference on Wednesday, August 9, 2023 at the InterContinental Boston Hotel. The Company's presentation is... Read More
ATLANTA , July 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2023 financial results will be released on Thursday, August 3, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session... Read More
Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA , May 23, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) granted premarket application... Read More
First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis On-X revenues increased 23% on a GAAP basis and 24% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022 Aortic stent... Read More
ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial results will be released on Thursday, May 4, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session... Read More
ATLANTA , April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22 nd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 8:45 a.m. ET on April 18 , 2023. A live webcast of the virtual fireside chat will be accessible through... Read More
ATLANTA , March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 33 rd Annual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 3:20 p.m. ET on March 14 , 2023. A live webcast of the virtual fireside chat will be accessible through... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB